



Modeling effect: How treatment intensity and duration impact depression recurrence

Fang Li^{1,4} , Qingyang Shi¹, Ellen Visser² , Robert A. Schoevers²,
Talitha Feenstra^{1,3}  and Frederike Jörg² 

Research Article

Cite this article: Li F, Shi Q, Visser E, Schoevers RA, Feenstra T, Jörg F (2026). Modeling effect: How treatment intensity and duration impact depression recurrence. *European Psychiatry*, **69**(1), e9, 1–8
<https://doi.org/10.1192/j.eurpsy.2025.10145>

Received: 03 July 2025

Revised: 28 October 2025

Accepted: 29 October 2025

Keywords:

depression recurrence; individualized treatment; real-world data; treatment intensity

Corresponding author:

Fang Li;

Email: fang.li@psych.ox.ac.uk

¹University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, Groningen, the Netherlands; ²University of Groningen, University Medical Center Groningen, University Center Psychiatry, Rob Giel Research Center, Interdisciplinary Centre for Psychopathology and Emotion Regulation, the Netherlands; ³Center for Nutrition, Prevention and Health Services Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands and ⁴Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom

Abstract

Background. Optimizing depression treatment intensity and duration is crucial, given an overburdened mental healthcare system. However, decision-making is challenged by heterogeneous treatment effects. We aimed to investigate these effects, accounting for confounders and population heterogeneity, in a real-world dataset from specialized mental healthcare.

Methods. The study included 36,946 participants from mental healthcare providers in the Northern Netherlands. We measured the effects of treatment duration and intensity on time to depression recurrence, using monthly costs as a proxy for treatment intensity. An accelerated failure time model was used, adjusting for confounding via entropy weighting. Non-linear effects were examined using restricted cubic splines to identify turning points, after which linear analyses were stratified. Population heterogeneity was explored through K-means clustering analyses, followed by cluster-specific analyses.

Results. In the high-intensity group (above €360/month), a €1000/month increase in treatment intensity may reduce time to recurrence by 16% (acceleration factor [AF] 0.84, 95% CI 0.77–0.92). Conversely, the same increase in the low-intensity group might prolong recurrence-free time by 9.6-fold (AF 9.6, 95% CI 2.18–42.31). Extending treatment duration by 6 months may reduce time to recurrence by 7% (AF 0.93, 95% CI 0.89–0.97) in the long-duration group, with no significant effect in the short-duration group. Five clusters emerged, three of which comprised only women, with AFs of 0.67, 0.80, and 0.81, respectively, under high treatment intensity.

Conclusions. Increasing treatment intensity appears worthwhile only in the low-intensity group, though residual confounding remains possible.

Background

Major depressive disorder (MDD) impacts over 300 million people globally [1], increasing the risk of suicide [2, 3] and overall mortality [4], and impairing occupational performance and overall quality of life [5], thereby imposing a high burden on society and healthcare systems [6]. MDD is highly recurrent, with a 60% recurrence rate within 5 years, 67% within 10 years, and 85% within 15 years [7]. Taken together, these characteristics illustrate the impressive burden of MDD on the mental healthcare system, which is often challenged by insufficient funding and staff. Developing a better understanding of the factors that impact recurrence and finding strategies to reduce this recurrence rate are crucial.

Several risk factors for the recurrence of MDD have been identified, with the baseline severity of an index episode providing the most evidence [8–14]. The severity of the index episode not only predicts recurrence but is also associated with treatment duration [10, 15, 16]. In addition, the chance of having an MDD recurrence is associated with the number of previous episodes [17]. The presence of comorbid psychiatric disorders [7, 9, 10, 18, 19] as well as residual symptoms after treatment [7, 20] also increases the likelihood of recurrence. Ongoing research is exploring other potential factors, such as neurocognitive function [21], cognitive bias [22], and time to clinical response [23]. Evidence regarding the influence of family history, social support, low socioeconomic status, and stressful life events is still limited due to methodological constraints [7, 24].

The roles of treatment intensity and duration during the index episode in recurrence have scarcely been studied. Existing evidence [25] suggests that longer illness duration before treatment initiation correlates with a higher probability of depressive episodes recurring. Additionally, research has explored how the recurrence rate is affected by the length of maintenance treatment. These studies suggest that while maintenance treatment can reduce the recurrence rate in the short term, extended maintenance treatment may not offer significant long-term benefits [26, 27]. However, these studies did not specifically investigate how the duration and intensity of

© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<http://creativecommons.org/licenses/by-nc-sa/4.0>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press or the rights holder(s) must be obtained prior to any commercial use.



treatment during the index episode might also influence time to recurrence. One study suggests that a shorter treatment duration of the index episode might lead to a higher risk of relapse and recurrence, but this finding was confounded by the number of previous episodes [28].

Furthermore, heterogeneity among MDD patients complicates treatment [29]. Understanding this heterogeneity, by identifying more homogeneous groups within the depressed patient population, is essential, as different subgroups may have varied treatment needs. These subgroups may respond differently to treatments and show varying recurrence patterns [23]. The differences among these groups will help shed light on the underlying causes of disparity in treatment outcomes and recurrence rates. Group classifications are typically based on variables such as gender, age, diagnoses, severity of the disorder, the presence of comorbid conditions, and history of suicide attempts [30].

Preventing recurrence of depressive episodes is a central aim of treatment [31]. It is relevant to explore how the intensity and duration of treatment correlate with the time until a depressive episode recurs, both in the whole cohort and within specific subgroups. Such analysis can provide insights for customizing treatment effectively. Insufficient treatment duration or inadequate intensity may fall short of preventing recurrence [28]. Conversely, excessively prolonged treatment duration may not offer additional benefits in preventing recurrence and may potentially strain healthcare resources, leading to increased waiting times for new clients [32].

Our study aimed to analyze how treatment intensity and duration affect time to recurrence using real-world data, adjusting for potential confounders. We also aimed to use cluster analysis to identify subgroups and examine how the effects varied among these groups.

Methods

Study setting and data source

This study used an administrative database containing individual-level data of specialist mental healthcare clients in the northern Netherlands, covering January 2004 to February 2020. Data include demographic and clinical variables, the results of Routine Outcome Monitoring (ROM) questionnaires filled out by clients, primary diagnostic categories according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [33], and detailed mental health service utilization.

Participants

The sample included 36,946 clients diagnosed with unipolar depression at the initial assessment. Clients treated for under 30 days or those without pre-treatment ROM scores within ± 30 days of initiation were excluded. To ensure a minimum two-year follow-up period for each patient, only those clients whose treatment ended before December 2017 were included. The study was based on pseudonymized administrative healthcare data for which no ethical approval was needed.

Outcome

The main outcome was time to recurrence of depression, defined as the initiation of a new treatment episode following a 6-month service-free period. This definition has been validated in previous studies using the same Dutch mental health dataset [34, 35]. For

clients with multiple episodes, the second-to-last was the index episode; single episodes without recurrence served as the index.

Exposures

Treatment duration, measured in months, was determined by calculating the interval between two dates: the start of the index episode, which is the first face-to-face diagnostic contact of the clients with the clinician, and the date of the last in-person treatment session [36]. Treatment intensity was quantified as the total cost of treatment divided by its overall duration in the index episode. To calculate costs, the service durations of various healthcare professionals were multiplied by their respective unit costs, price year 2019 [37]. These unit costs, based on professional salary levels, were derived from the Dutch costing manual for health economic evaluations [38] and were hence fixed across patients and providers, with the corresponding unit prices detailed in [Supplementary Table S1](#). Detailed information on service types, contact times, and associated costs is provided in [Supplementary Table S2](#).

Covariates and measurements

Six covariates were used to adjust for confounding and cluster classification: baseline severity of the index episode (measured by the Outcome Questionnaire-45, where lower scores indicate better functioning), comorbidity, the number of previous treatment episodes, antidepressant use during the index episode (yes/no), age, and gender. Comorbidity was grouped into three categories: only personality disorders, only other psychiatric conditions (e.g., anxiety, sleep disorders, ADHD), or both, due to the low prevalence of non-personality psychiatric conditions.

Statistical analysis

We employed the entropy weighting method, assigning weights to covariates based on their importance and variability, to adjust for confounding factors affecting the relationship between treatment intensity, duration, and recurrence [39]. Next, the generalized gamma distribution was selected for modeling time to recurrence based on the Akaike Information Criterion ([Supplementary Table S3](#)) and validated using a 75–25% training-validation split ([Supplementary Figures S2 and S3](#)). Restricted cubic splines were used to capture non-linear exposure relationships, as this approach flexibly identifies dose-response patterns without arbitrary categorization while mitigating overfitting, and has also been applied in the field of depression care before, though during a different treatment phase [40]. Knots were placed at the 25th, 50th, and 75th percentiles, consistent with established practice [40, 41]. Numerical differentiation identified turning points. To facilitate interpretation, we divided the entire population into two groups based on this turning point and applied the model with a linear spline to these groups. Specifically, clients with treatment intensity below the turning point were placed in the low-intensity group, while those above were assigned to the high-intensity group. Similarly, treatment durations shorter than the turning point were categorized as the short-duration group, whereas durations exceeding this point were considered the long-duration group. The analysis finally employed a weighted generalized gamma accelerated failure time (AFT) model with entropy weights. As the proportional hazards assumption had been violated, we chose the AFT model to examine the effects of treatment

intensity and duration on the time to recurrence [42]. In the AFT model, an acceleration factor (AF) exceeding one signifies an extended time to recurrence, whereas an AF below one indicates a reduced time to recurrence.

Clustering analysis was conducted to address population heterogeneity by identifying clusters. Models were also fitted by clusters to evaluate the effects of exposures on outcomes with clusters. We employed K-means with Gower distance [43] as a clustering technique. Clusters were classified based on five variables, as identified in existing literature: age [7], gender [23], prior treatment episodes (yes/no) [22, 44], comorbidities [7], and baseline severity [7]. The number of clusters was established by iteratively repeating clustering and then selecting optimal clusters based on the Silhouette Width and Within-Cluster Sum of Squares with 100 bootstraps [45].

Sensitivity analysis

Given the potential selection bias due to the substantial exclusion of data in the main analysis, we employed an imputation approach for handling missing data, where each missing value was imputed using Bayesian linear regression [42], generating plausible values by sampling from posterior predictive distributions based on observed covariates, thereby preserving both statistical relationships and appropriate uncertainty in the imputed values. Following the imputation process, we re-conducted the analysis on the larger dataset using the imputed data. Additionally, we tested the robustness of our spline models using alternative knot placements (3, 4, and 5 knots) following Harrell's recommendations [41].

Results

A total of 36,946 clients were diagnosed with MDD between 2004 and 2020. Among them, 27,276 were excluded due to the absence of baseline severity data of the index episode, resulting in 6,863 participants included in our study (see [Supplementary Figure S3](#)). The included participants were significantly younger (average age 41 years) than those excluded (average age 48 years). Over a 10-year follow-up, the included group had a shorter time to

recurrence (42.82 months) compared to the excluded group (50.39 months) ([Table 1](#)).

[Supplementary Figure S4](#) presents the correlation between six covariates and two exposures before and after entropy weighting. Before adjustment, the severity of the index episode, antidepressant use, and the presence of comorbidities were associated with both treatment duration and treatment intensity, while the number of previous treatment episodes and clients' age were only correlated with treatment intensity. These associations had modest effect sizes.

The linearity assessment revealed a non-linear relationship between exposures and recurrence ([Supplementary Figures S5 and S6](#)). Within the entire cohort, the turning point for treatment intensity was €360/month ([Table 2](#)). For clients undergoing treatment above this threshold, referred to as the high-intensity group, the AFT model showed an acceleration factor of 0.841 (95% CI: 0.770–0.918). This indicates that each €1000/month increase in treatment intensity was associated with a 15.9% (95% CI: 8.2–23.0%) shorter time to recurrence. Conversely, for clients with treatment intensities below this threshold, referred to as the low-intensity group, the AFT model showed a significantly higher acceleration factor of 9.599 (95% CI: 2.177–42.31), suggesting that each €1000/month increase in treatment intensity was associated with a 9.6-fold longer time to recurrence. Regarding treatment duration, the turning point within the whole cohort was 7.8 months. The long-duration group had an acceleration factor of 0.928 (95% CI: 0.886–0.973), indicating that a six-month extension in treatment duration was associated with a 7.2% (95% CI: 2.7–11.4%) shorter time to recurrence. No significant association was observed for the short-duration group ([Table 3](#)).

Cluster analysis identified five groups (Clusters 1–5). A graphical representation of this analysis is available in [Supplementary Figure S7](#). Variations in the recurrence rates across these clusters are illustrated in [Figure 1](#). Cluster 1 (female clients with depression only) had the lowest recurrence rate at 18%, while Cluster 5 (female clients with MDD, personality disorder, and comorbidities) had the highest at about 60%. Generalized gamma distribution parameters are reported in [Supplementary Table S4](#).

The AFT models showed that Clusters 1, 4, and 5 had similar patterns to the whole cohort in the high-intensity group ([Figure 2](#)), with higher treatment intensity associated with shorter time to

Table 1. Baseline characteristics and outcome in included and excluded groups

Measures		Included group (N = 6,863)	Excluded group (N = 27,276)	p-value ^a
Age (mean (SD))		40.33(13.16)	46.80(19.25)	<0.001
Gender-female (%)		3,935 (57.30)	16,259 (59.60)	0.100
Number of prior treatment episodes (%)	0	6,317(92.04)	25,205(92.40)	0.330
	>= 1	546(7.960)	2,071 (7.600)	
Comorbidities (%)	MDD only	3,772 (55.00)	14,044 (51.50)	0.090
	MDD and PD	1,317 (19.20)	5,906 (21.70)	
	MDD and other comorbidities	778 (11.30)	3,036 (11.10)	
	MDD, PD and other comorbidities	996 (14.50)	4,290 (15.70)	
Total OQ45 at baseline (mean (SD))		88.10(22.00)	NA	-
Time to recurrence (months), (mean (SD))		42.82(31.85)	50.39(37.56)	<0.001

Abbreviations: MDD, major depressive disorder; PD, personality disorder.


^aStatistical comparisons between the two groups were performed using a chi-square test for categorical variables, and a t-test for continuous variables.

Table 2. The effect of treatment intensity in the complete cohort and by cluster

Clusters	Turning point (1000€/month)	N (low intensity)	Effect of intensity (1000€/month 95% CI)	p-value	N (high intensity)	Effect of intensity (1000€/month 95% CI)	p-value
Whole cohort	0.360	3,972	9.599 (2.177–42.31)	<0.001	2,891	0.841(0.770–0.918)	<0.001
Cluster 1	0.330	1,296	15.20 (0.463–499.9)	0.127	1,030	0.669(0.552–0.808)	<0.001
Cluster 2	0.450	582	5.190 (0.471–57.15)	0.179	316	1.031 (0.857–1.241)	0.741
Cluster 3	0.340	1,106	19.39 (0.610–616.9)	0.092	821	0.848 (0.664–1.082)	0.186
Cluster 4	0.500	598	5.222 (0.375–72.76)	0.218	248	0.798 (0.638–0.996)	<0.001
Cluster 5	0.260	260	8.923 (0.0457–174.4)	0.416	606	0.807 (0.689–0.946)	<0.001

Table 3. The effect of treatment duration in the complete cohort and by cluster

Clusters	Turning point (months)	N (short duration group)	Effect of duration (6 months 95% CI)	p-value	N (long duration group)	Effect of duration (6 months 95% CI)	p-value
Whole cohort	7.8	2,508	1.062(0.649–1.737)	0.810	4,355	0.928(0.886–0.973)	<0.001
Cluster 1	7.8	986	1.326(0.536–3.280)	0.540	1,340	0.868(0.762–0.988)	<0.05
Cluster 2	7.6	270	0.539(0.136–2.135)	0.332	628	0.957(0.876–1.046)	0.379
Cluster 3	6.0	576	1.346(0.314–5.776)	0.689	1351	0.879(0.768–1.005)	0.059
Cluster 4	6.2	215	0.845(0.086–8.546)	0.268	631	1.090(0.963–1.233)	0.268
Cluster 5	11.5	271	2.211(1.237–3.954)	<0.00	595	0.951(0.876–1.032)	0.225

**Figure 1.** Cumulative incidence of recurrence across five clusters. CM, comorbidity; MDD, major depressive disorder; PD, personality disorder.

recurrence. In contrast, the low-intensity group showed no significant associations. Clusters 2 and 3 showed no significant associations with recurrence time in either group. Cluster 4 had the highest turning point at €500/month.

Regarding treatment duration, Cluster 1 displayed an AF of 0.868 (95% CI: 0.762–0.988), indicating that longer treatment duration was associated with shorter time to recurrence in the

long-duration group. Cluster 5 showed an AF of 2.2 in the short-duration group, suggesting an association with longer time to recurrence. No significant associations with time to recurrence were observed in the other clusters. Cluster 5 had the largest turning point for treatment duration at 11.5 months.

Results from the sensitivity analysis, conducted on an imputed dataset comprising 34,139 cases, aligned with the




Figure 2. Clustering for recurrence rate and effect treatment intensity in high-intensity group. BS, baseline symptom score; CM, comorbidity; MDD, major depressive disorder; PD, personality disorder; PE, previous episode.

findings of the main analysis (Supplementary Tables S5 and S6). The non-linear relationships for treatment intensity and duration are shown in Supplementary Figures S8 and S9. Higher treatment intensity in the low-intensity group was associated with extended time to recurrence, while in the high-intensity group, it was associated with shorter time to recurrence. The turning point for treatment intensity in this larger dataset was €340/month for the whole cohort, aligning closely with €360/month from the main analysis.

The turning points of treatment intensity for each cluster ranged from €320/month to €390/month, with Cluster 5 having the highest at €390/month. As in the main analysis, longer treatment duration in the long-duration group was associated with shorter time to recurrence. In the sensitivity analysis, effects were significant across all clusters in the long-duration group, with Cluster 5 showing the largest turning point at 19.5 months. Effects in short-duration groups were not statistically significant. In sensitivity analyses examining knot placement, the non-linear relationship remained stable across all alternative knot placements tested as shown in Supplementary Figure S10, with turning points ranging from €300 to 340/month, closely approximating our main estimate of €360/month.

Discussion

This study found that increasing treatment intensity may potentially extend the time to recurrence in the group receiving low treatment intensity, after adjusting for confounders. Conversely, for clients in the high-intensity group, an increase in treatment intensity appeared to shorten the time to recurrence. These results suggest a non-linear relationship between treatment intensity and recurrence, which was supported by the linearity check. Our

analysis also showed that extended treatment duration reduced the time to recurrence in clients with longer treatment duration, while no significant effect of treatment duration was observed on the time to recurrence in the short-duration group.

To the best of our knowledge, this was the first study to use extensive longitudinal data to explore the effects of treatment intensity and duration on recurrence, accounting for potential confounders, and hence comparisons with similar studies are challenging. Our research found no evidence of an association between extending treatment duration and time to recurrence in the short-duration group, defined as clients with treatment durations below 7.8 months. This finding remains robust even after adjusting for confounders, such as baseline symptom scores. Consistent findings were also observed in a larger, imputed dataset. Additionally, results indicate that for clients receiving treatment at an intensity below the average turning point of €360/month, higher treatment intensity was associated with longer time to recurrence. This observation could be interpreted as suggesting that low treatment intensity in this group may result in residual symptoms, which subsequently lead to rapid recurrence of depressive symptoms [20]. In the high-treatment intensity group, however, further increases in treatment intensity were associated with shorter time to recurrence. This could have at least two possible explanations: first, clients may develop a dependency on the treatment or therapist, leading to increased difficulty in discontinuing treatment, which in turn increases the likelihood of recurrence. Second, the presence of unaddressed confounding factors could also contribute to this outcome.

In the literature, a similar non-linear relationship was observed between the total number of treatment sessions and symptom improvement. Shorter treatments with fewer sessions typically lead to faster improvement, while longer durations result in

slower gains. However, the optimal number of sessions, or “turning point,” varies across studies, with some suggesting eight sessions as the turning point, beyond which no additional benefit is observed [46–48]. Other studies recommend 10 to 16 sessions [49, 50], while one found the maximum benefit at 25 sessions, noting diminishing returns after that [51]. Despite variations in settings, populations, and outcome measures, these findings support our conclusion that extended treatment duration may not enhance treatment outcome [52].

Our cluster analysis identified five groups with varying recurrence rates. Cluster 1 had the lowest recurrence rate, likely due to its composition of female clients with MDD, who tend to respond better to treatment [53]. In contrast, Cluster 5 had the highest recurrence rate. This can be ascribed to the complexity of the client profiles within this cluster, which includes individuals with MDD in combination with comorbid personality disorders and other psychiatric conditions, presenting a more challenging scenario to prevent or postpone recurrence [54]. This result is consistent with a previous study [10], indicating that clients with more comorbidities are more likely to experience a recurrence. Notably, our observations indicated a 30% recurrence rate in the entire cohort, lower than the rates reported in prior studies [7]. Two possible explanations for this difference might be: first, the minimum duration of our follow-up period is 2 years, which raises the possibility that some clients may not have experienced a relapse within this timeframe; second, our definition of recurrence is re-entering the healthcare service provider’s system. However, a relapse can also occur during the treatment process and may thus not be identified in our data.

The cluster analysis revealed a non-linear relationship between exposures, treatment duration and intensity, and the time to recurrence. In these clusters, consisting of female clients diagnosed with depression, with and without additional comorbidities, or with personality disorders and other comorbid conditions, increasing treatment intensity may be harmful. In the sensitivity analysis, treatment intensity significantly impacted outcomes in all clusters except Cluster 5, following the same trend as the whole cohort. Treatment duration significantly affected outcomes only in Cluster 1 in the main analysis, but did not extend beyond Cluster 1 in the long-duration group during the sensitivity analysis, potentially due to the large imputed sample. Cluster 5 had the highest turning points for both treatment duration and intensity, likely due to the complex conditions of clients with multiple comorbidities.

Our results highlight the importance of estimating treatment intensity and duration to determine the optimal treatment strategies for individuals. Clinicians are advised to closely monitor clients, especially individuals diagnosed with depression, personality disorders, and other comorbidities. Although these clients require relatively longer treatment durations and slightly higher treatment intensity to reach their turning point compared to other clusters, there is no evidence that increasing treatment intensity beyond this point prolongs the time to recurrence for this group. Such attention is essential, considering the limited benefits of excessive treatments and the common belief that more comorbidities need more extensive treatment [55]. Effective monitoring and appropriate treatment adjustment are key to enhancing client outcomes. This could also lead to more efficient resource allocation, allowing for shorter waiting times for new clients and improving the overall quality of care.

Given the pandemic-related shifts in prevalence and service delivery, we next consider the applicability of our findings to current practice in the Netherlands. Our data extend only until

February 2020 due to availability; thus, the cohort primarily reflects pre-pandemic care patterns. During the pandemic, depression prevalence fluctuated in line with public health restrictions, and services shifted from face-to-face to tele-mental care. Overall contact volumes were maintained in the large Dutch providers [56] during the pandemic, and tele-mental care has been shown to achieve outcomes comparable to those of in-person care [57]. Nowadays, a mix of in-person and tele-mental care is provided. We estimated the associations between treatment intensity and duration and time to recurrence, adjusting for confounders, with intensity defined as unit costs multiplied by clinician time per month, rather than by the mode of delivery. The therapeutic mechanisms linking treatment intensity and duration to time to recurrence, such as skill acquisition, symptom monitoring, and therapeutic alliance, remain operative regardless of delivery modality [58]. On this basis, we expect the direction and overall pattern of associations between intensity/duration and recurrence to generalize to current practice, although the turning points of treatment intensity may have shifted after 2020, calling for external validation in post-2020 cohorts.

This study should be seen in light of several strengths and limitations. First, our analyses were not specific to any single treatment modality, but rather included all treatments received, irrespective of treatment type. This reflects the fact that the vast majority of Dutch patients (approximately 95%) receive multi-modal care. Additional analyses conducted for the small subgroup of CBT-only patients yielded similar patterns, although these were not statistically significant due to the limited sample size (see [Supplementary Figure S11](#) and [Table S7](#)). Second, a large number of clients were excluded due to the absence of their baseline severity scores, which are essential to adjust for confounding. Clients who were excluded were, on average, older, but did not differ in other available demographics. The correlation between baseline severity and treatment intensity and duration, as confirmed by the results of entropy balancing weights, aligns with previous research [10, 15]. The outcomes of our sensitivity analysis on the imputed dataset are consistent with our primary analysis, suggesting that the selection bias resulting from the absence of baseline severity scores may not have significantly impacted our findings. It is important to note that we only employed simple imputation to address missing data, as further steps such as confounder correction and cluster identification, were also necessary before modeling effects.

Third, the main analysis may not accurately pinpoint the turning point for each individual within clusters, leading to relatively wide confidence intervals in the low-intensity group. This issue likely arises from the small sample sizes within each cluster. To address this concern, we conducted sensitivity analyses using a larger imputed dataset, which not only helped narrow the confidence intervals but also further confirmed the robustness of our model. However, this limitation highlights the need for further research employing more sophisticated methods to determine optimal treatment duration and intensity on an individual basis. Furthermore, residual confounding by baseline depression severity may exist despite OQ-45 adjustment. The low-intensity group could consist of a mix of mild cases, non-adherent patients, and fast responders. Future research should use comprehensive severity measures to separate true intensity effects from selection bias. Additional unmeasured confounders, including genetic factors and neurocognitive functioning, may also have influenced our results. Finally, our recurrence definition, based on 6-month treatment gaps, may misclassify some dropouts or non-adherent

patients as remitted, potentially biasing recurrence estimates in either direction.

Strong points of our study include the unique dataset with a reasonably large sample size of nearly 7,000 individuals, with at least 2 years and up to 10 years of follow-up. This provides insights into long-term recurrence patterns in a real-world context. We observed that recurrence rates and the effects of treatment duration and intensity varied across different clusters after adjusting for confounding, enriching our understanding of the impact of treatment intensity and duration on the time to recurrence. It is noteworthy that, at least in the high-intensity group, further increasing the intensity or duration of treatment may not yield additional benefits and could even be harmful. This insight is helpful for decision-makers aiming to optimize treatment strategies in a cost-effective manner. Nonetheless, these results should be interpreted with caution due to the potential presence of other residual confounding factors. Finally, the generalized gamma distribution for time to recurrence offers relevant input for future studies that need detailed information about the time until depression re-occurs, such as in health economic decision models.

Conclusion

Higher treatment intensity was associated with longer time to recurrence in the low-intensity treatment group, even after accounting for confounding factors, suggesting potential value in more intensive treatment. Conversely, in the high-intensity treatment group, greater treatment intensity was associated with significantly shorter time to recurrence, which could indicate that intensity increases beyond this threshold did not offer additional benefits. These observations highlight the importance of matching treatment intensity to suit the specific needs of each client. Moreover, cluster analyses showed variation in how treatment intensity affects time to recurrence across patient subgroups, suggesting that individualized treatment approaches warrant further investigation. These findings should be interpreted with caution, as this is an observational study. Despite our efforts to control for all potential confounders, some residual confounding may still be present.

Supplementary material. The supplementary material for this article can be found at <http://doi.org/10.1192/j.eurpsy.2025.10145>.

Data availability statement. Data may be obtained from a third party and are not publicly available. The programming code will be made available upon reasonable request to the corresponding author.

Acknowledgements. We thank Yiling Zhou, Maarten Brilman, and Stijn de Vos for their constructive suggestions for this study.

Funding statement. The development of the data infrastructure for this study was supported by Stichting De Friesland, Leeuwarden, the Netherlands (grant number DS29). Stichting De Friesland had no role in the study design, analysis, and interpretation of the data; report writing; or the decision to submit the article for publication. FL was awarded a personal scholarship from the China Scholarship Council (CSC) under the file number 202006050038, while conducting this work. Open access funding provided by University of Groningen.

Competing interests. The authors declare none.

References

- [1] Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2024;403(10440):2133–61.
- [2] Choo C, Diederich J, Song I, Ho R. Cluster analysis reveals risk factors for repeated suicide attempts in a multi-ethnic Asian population. *Asian J Psychiatr*. 2014;8:38–42.
- [3] Large M. Study on suicide risk assessment in mental illness underestimates inpatient suicide risk. *BMJ*. 2016;352.
- [4] Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. *J Affect Disord*. 2002;72(3):227–36.
- [5] Trivedi MH, Wisniewski SR, Nierenberg AA, Gaynes BN, Warden D, Morris M, et al. Health-related quality of life in depression: a STAR* D report. *Ann Clin Psychiatry*. 2010;22(1):43–55.
- [6] Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. *JAMA*. 2003;289(23):3135–44.
- [7] Hardeveld F, Spijker J, De Graaf R, Nolen W, Beekman A. Prevalence and predictors of recurrence of major depressive disorder in the adult population. *Acta Psychiatr Scand*. 2010;122(3):184–91.
- [8] Gopinath S, Katon WJ, Russo JE, Ludman EJ. Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. *J Affect Disord*. 2007;101(1–3):57–63.
- [9] Holma KM, Holma IA, Melartin TK, Rytala HJ, Isometsa ET. Long-term outcome of major depressive disorder in psychiatric patients is variable. *J Clin Psychiatry*. 2008;69(2):196–205.
- [10] Melartin TK, Rytala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. *J Clin Psychiatry*. 2004;65(6):810–9.
- [11] Ramana R, Paykel E, Cooper Z, Hayhurst H, Saxty M, Surtees P. Remission and relapse in major depression: a two-year prospective follow-up study. *Psychol Med*. 1995;25(6):1161–70.
- [12] Pintor L, Torres X, Navarro V, Matrai S, Gastó C. Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up? *J Affect Disord*. 2004;82(2):291–6.
- [13] Kennedy N, Abbott R, Paykel E. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. *Psychol Med*. 2003;33(5):827–38.
- [14] Klein NS, Holtman GA, Bockting CL, Heymans MW, Burger H. Development and validation of a clinical prediction tool to estimate the individual risk of depressive relapse or recurrence in individuals with recurrent depression. *J Psychiatr Res*. 2018;104:1–7.
- [15] Spijker J, De Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Br J Psychiatry*. 2002;181(3):208–13.
- [16] Cohen RB, Brunoni AR, Boggio PS, Fregni F. Clinical predictors associated with duration of repetitive transcranial magnetic stimulation treatment for remission in bipolar depression: a naturalistic study. *J Nerv Ment Dis*. 2010;198(9):679–81.
- [17] Bulloch A, Williams J, Lavorato D, Patten S. Recurrence of major depressive episodes is strongly dependent on the number of previous episodes. *Depress Anxiety*. 2014;31(1):72–6.
- [18] Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL. Double depression”: two-year follow-up. *Am J Psychiatry*. 1983;140(6):689–94.
- [19] Hoertel N, Blanco C, Oquendo MA, Wall MM, Olfson M, Falissard B, et al. A comprehensive model of predictors of persistence and recurrence in adults with major depression: results from a national 3-year prospective study. *J Psychiatr Res*. 2017;95:19–27.
- [20] Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T, et al. Time to recurrence after recovery from major depressive episodes and its predictors. *Psychol Med*. 2003;33(5):839–45.
- [21] Wang M, Liu Q, Yang X, Dou Y, Wang Y, Zhang Z, et al. Relationship of insight to neurocognitive function and risk of recurrence in depression: A naturalistic follow-up study. *Front Psych* 2023;14:1084993.
- [22] Beshai S, Dobson KS, Bockting CL, Quigley L. Relapse and recurrence prevention in depression: current research and future prospects. *Clin Psychol Rev*. 2011;31(8):1349–60.

- [23] Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. *Lancet Psychiatry*. 2017;4(3):230–7.
- [24] Buckman JE, Underwood A, Clarke K, Saunders R, Hollon S, Fearon P, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis. *Clin Psychol Rev*. 2018;64:13–38.
- [25] Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. *Am J Psychiatry*. 1999;156(7):1000–6.
- [26] Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. *Am J Psychiatry*. 1998;155(9):1247–53.
- [27] Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. *Am J Psychiatry*. 2016;173(2):128–37.
- [28] Berlanga C, Heinze G, Torres M, Apiquián R, Caballero A. Personality and clinical predictors of recurrence of depression. *Psychiatr Serv*. 1999;50(3):376–80.
- [29] Banerjee S, Wu Y, Bingham KS, Marino P, Meyers BS, Mulsant BH, et al. Trajectories of remitted psychotic depression: identification of predictors of worsening by machine learning. *Psychol Med*. 2023;1–10.
- [30] Musliner KL, Munk-Olsen T, Laursen TM, Eaton WW, Zandi PP, Mortensen PB. Heterogeneity in 10-year course trajectories of moderate to severe major depressive disorder: a Danish national register-based study. *JAMA Psychiatry*. 2016;73(4):346–53.
- [31] Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, et al. Time for united action on depression: a Lancet–World Psychiatric Association Commission. *Lancet*. 2022;399(10328):957–1022.
- [32] Ismail H. Duration of hospital admission in severe mental illness: is longer better? *BJPsych Adv*. 2021;27(4):213–8.
- [33] American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-5*. Arlington; 2013.
- [34] Kan K, Lokkerbol J, Jörg F, Visser E, Schoevers RA, Feenstra TL. Real-world treatment costs and care utilization in patients with major depressive disorder with and without psychiatric comorbidities in specialist mental healthcare. *Pharmacoeconomics*. 2021;39(6):721–30.
- [35] Li F, Visser E, Brilman M, de Vries SO, Goeree B, Feenstra T, et al. Comparative analysis of algorithm-guided treatment and predefined duration treatment programmes for depression: exploring cost-effectiveness using routine care data. *BMJ Ment Health*. 2023;26(1).
- [36] De Beurs E, Warmerdam E, Oudejans S, Spits M, Dingemans P, De Graaf S, et al. Treatment outcome, duration, and costs: a comparison of performance indicators using data from eight mental health care providers in the Netherlands. *Adm Policy Ment Health Ment Health Serv Res*. 2018;45:212–23.
- [37] Konings SR, Bruggeman R, Visser E, Schoevers RA, Mierau JO, Feenstra TL. Episode detection based on personalized intensity of care thresholds: a schizophrenia case study. *Soc Sci Med*. 2021;270:113507.
- [38] Institute DNH. *Costing manual: methods and reference prices for economic evaluations in healthcare 2024 version*; 2024.
- [39] Hainmueller J. Entropy balancing for causal effects: A multivariate reweighting method to produce balanced samples in observational studies. *Polit Anal*. 2012;20(1):25–46.
- [40] Klein T, Breilmann J, Schneider C, Girlanda F, Fiedler I, Dawson S, et al. Dose–response relationship in cognitive behavioral therapy for depression: a nonlinear meta-regression analysis. *J Consult Clin Psychol*. 2024;92(5):296.
- [41] Harrell FE. Ordinal logistic regression. In: *Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis*. Springer; 2015, p. 311–25.
- [42] Wei L-J. The accelerated failure time model: A useful alternative to the Cox regression model in survival analysis. *Stat Med*. 1992;11(14–15):1871–9.
- [43] Tuerhong G, Kim SB. Gower distance-based multivariate control charts for a mixture of continuous and categorical variables. *Expert Syst Appl*. 2014;41(4):1701–7.
- [44] Clarke K, Mayo-Wilson E, Kenny J, Pilling S. Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. *Clin Psychol Rev*. 2015;39:58–70.
- [45] Brusco MJ. A repetitive branch-and-bound procedure for minimum within-cluster sums of squares partitioning. *Psychometrika*. 2006;71:347–63.
- [46] Beail N, Kellett S, Newman DW, Warden S. The dose–effect relationship in psychodynamic psychotherapy with people with intellectual disabilities. *J Appl Res Intellect Disabil*. 2007;20(5):448–54.
- [47] Baldwin SA, Berkeljon A, Atkins DC, Olsen JA, Nielsen SL. Rates of change in naturalistic psychotherapy: Contrasting dose–effect and good-enough level models of change. *J Consult Clin Psychol*. 2009;77(2):203.
- [48] Erekson DM, Lambert MJ, Eggett DL. The relationship between session frequency and psychotherapy outcome in a naturalistic setting. *J Consult Clin Psychol*. 2015;83(6):1097.
- [49] Harnett P, O'Donovan A, Lambert MJ. The dose response relationship in psychotherapy: Implications for social policy. *Clin Psychol*. 2010;14(2):39–44.
- [50] Kopta SM, Howard KI, Lowry JL, Beutler LE. Patterns of symptomatic recovery in psychotherapy. *J Consult Clin Psychol*. 1994;62(5):1009.
- [51] Lincoln T, Jung E, Wiesjahn M, Schlier B. What is the minimal dose of cognitive behavior therapy for psychosis? An approximation using repeated assessments over 45 sessions. *Eur Psychiatry*. 2016;38:31–9.
- [52] Bone C, Delgado J, Barkham M. A systematic review and meta-analysis of the good-enough level (GEL) literature. *J Couns Psychol*. 2021;68(2):219.
- [53] Carter GC, Cantrell RA, Zarotsky V, Haynes VS, Phillips G, Alatorre CI, et al. Comprehensive review of factors implicated in the heterogeneity of response in depression. *Depress Anxiety*. 2012;29(4):340–54.
- [54] Newton-Howes G, Tyrer P, Johnson T, Mulder R, Kool S, Dekker J, et al. Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. *J Personal Disord*. 2014;28(4):577–93.
- [55] Dickinson LM, Dickinson WP, Rost K, DeGruy F, Emsermann C, Froshaug D, et al. Clinician burden and depression treatment: disentangling patient- and clinician-level effects of medical comorbidity. *J Gen Intern Med*. 2008;23:1763–9.
- [56] Chow MW, Noorthoorn EO, Wierdsma AI, Van Der Horst M, De Boer N, Guloksuz S, et al. Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health Centre: retrospective observational study. *BJPsych Open*. 2021;7(6):e213.
- [57] Sugarman DE, Busch AB. Telemental health for clinical assessment and treatment. *BMJ*. 2023;380.
- [58] Andersson G, Titov N, Dear BF, Rozental A, Carlbring P. Internet-delivered psychological treatments: From innovation to implementation. *World Psychiatry*. 2019;18(1):20–8.